Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epomediol is a synthetic terpenoid and small molecule with choleretic effects, meaning it stimulates bile production by the liver. It has been primarily used for the symptomatic treatment of pruritus (itching) associated with intrahepatic cholestasis of pregnancy[1][5][7]. Mechanistically, epomediol increases bile flow and enhances the secretion of bile acids and cholesterol by upregulating enzymes such as cholesterol 7alpha-hydroxylase in hepatocytes[4]. It can reverse ethinyloestradiol-induced cholestasis in animal models and restore normal hepatocyte bile acid uptake when administered in vivo alongside ethinyloestradiol[4][8]. Its action appears to be both independent from and additive to that of endogenous bile acids at low secretory rates[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on epomediol.